Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ramucirumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15372, I4T-MC-JVCU, 2014-002240-40, NCT02314117
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15540, I4T-MC-JVCY, 2014-004824-22, NCT02411448
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15679, I4T-MC-JVDC, 2014-003655-66, NCT02426125
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15755, I4T-MC-JVDE, 2014-005068-13, NCT02435433
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15246, I4C-MC-JTBF, NCT02082210
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GI 201, NCT02317991
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15608, I4T-MC-JVDB, 2014-003791-23, NCT02443883
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15233, I4T-CR-JVCQ, NCT02069041
A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15266, I3Y-MC-JPBJ, NCT02079636
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15532, I4T-JE-JVCX, NCT02359058
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15787, I4T-MC-JVDF, 2015-001473-40, NCT02443324
Start Over